Biotech · Private company · Bethesda, MD, US
AbViro LLC
Track this companyFree. Adds AbViro LLC to your Dealase workspace and tells you when its record changes.
Clinical trials20 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- AV-1 100 mgPhase 2 · DENV-3 Controlled Human Infection ModelClinicalTrials.gov · fetched Nov 12, 2026
- AV-1 300 mgPhase 2 · DENV-3 Controlled Human Infection ModelClinicalTrials.gov · fetched Nov 12, 2026
- AV-1 900 mgPhase 2 · DENV-3 Controlled Human Infection ModelClinicalTrials.gov · fetched Nov 12, 2026
- AV-1Phase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) InfectionPHASE2 · COMPLETED · started Jan 7, 2025ClinicalTrials.gov NCT06799741 · fetched Nov 12, 2026
- A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy VolunteersPHASE1 · COMPLETED · started Feb 4, 2020ClinicalTrials.gov NCT04273217 · fetched Nov 12, 2026
NIH awards2
- Development of Therapeutic Candidates for Biodefense, Infections and Emerging Infectious DiseasesFiscal year 2026 · $2.6MNIH RePORTER 75N93023C00055-P00007-9999-1 · fetched Nov 12, 2026
- Development of Therapeutic Candidates for Biodefense, Infections and Emerging Infectious DiseasesFiscal year 2024 · $7MNIH RePORTER 75N93023C00055-P00002-9999-1 · fetched Nov 12, 2026